Uncategorized-EN
From listening to action: Patients’ voices are shaping sarcoma care in Italy
Concrete improvements in sarcoma care in Italy are becoming a reality. The country’s first Sarcoma White Paper maps out 14 recommendations based on patients’ priorities, and its implementation has already begun. The Fondazione Paola Gonzato-Rete Sarcoma ETS, founded by Ornella Gonzato, was honored for this landmark initiative last May by SPAGN with an Advocacy in Action Award. Martina Gherlinzoni, a member of the Foundation’s Board of Directors, explains what makes their project so distinctive that it has become a major national news story in Italy.
Read MoreVacancy Announcement: Communications & Content Manager
We are hiring! Communications & Content Manager (m/f/d) Part-time, freelance, remote Approx. 40–60 hours per month, with flexibility depending on project needs and campaign activities You… An experienced communications professional with an interest in patient advocacy, healthcare, oncology, rare diseases or the pharmaceutical sector? Creative, hands-on and comfortable managing communications across multiple channels?…
Read MoreASCO 2026: Strong Momentum for Sarcoma Research
By Kathrin Schuster & Bernd Kasper, June 2026 ASCO 2026 was a remarkable year for sarcoma research: The program included several phase III trials, new targeted therapies, cell therapy approaches, translational research, and biomarker-driven strategies, reflecting the continued evolution of the field. Compared with previous years, sarcoma had a particularly visible presence at this year’s…
Read MoreSTC-15
STC-15 in Combination With Toripalimab in Selected Advanced Cancers and as Monotherapy in Selected Sarcomas Agent: STC-15 (a METTL3 inhibitor) Phase Ib/II Status Recruiting Sponsor STORM Therapeutics LTD For further information please also consult https://clinicaltrials.gov/study/NCT06975293 This is an open-label, non-randomized, multi-cohort, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of STC-15 (a…
Read MoreSPAGN Annual Conference 2026 Highlights ✨
Photos: Uli Deck A Global Community United by Hope and Collaboration The SPAGN Annual Conference 2026, held in Stockholm, Sweden at Karolinska University Hospital and Elite Hotel Carolina Tower, once again demonstrated the strength, warmth, and determination of the global sarcoma community. Bringing together patients, advocates, healthcare professionals, researchers, and industry partners from around the…
Read MoreBy bike from Berlin to the Taj Mahal: Young Ewing sarcoma survivor starts charity tour
At the age of 22, John Müller was diagnosed with an Ewing sarcoma, followed by ten months of multimodal therapy. Three years later, he plans to set off by bicycle from Germany to India. His goal: to raise awareness of Ewing sarcomas and to mobilize donations for an emergency fund for sarcoma patients, particularly adolescents and young adults (AYA). Shortly before the start of his journey, John spoke with Voices of Sarcoma.
Read MoreUSA: Rutledge Cancer Foundation
USA: Rutledge Cancer Foundation Back to members Organisation Profile Patient Support and Resources They fund programs and provide resources to meet the emotional and physical needs of AYA patients with cancer — offering support where it’s needed most. About the Research They Fund They focus on funding research and clinical trials…
Read MoreKey Take-Aways for Patients from EMSOS 2026
EMSOS is a leading European society focused on musculoskeletal oncology. Each year, the congress brings specialists together to share the latest insights, treatments, and research results. The 2026 edition took place in Portugal. What also stood out was that the congress was not only about doctors and treating specialists. Researchers, students, psychologists, and other healthcare…
Read MoreROGER EXPLORES… Immunotherapy
Immunotherapy has transformed cancer treatment in recent years by harnessing the body’s own immune system to identify and fight tumour cells. But, its application in the treatment of sarcomas is still limited. Roger Wilson explains here some basics of immunotherapy, the implications for sarcoma patients and points to some studies. A Beginners’ guide on immunotherapy for sarcoma patients.
Read MoreTebentafusp in HLA-A*02:01 Positive Patients with advanced Clear Cell Sarcoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Agent: Tebentafusp vs. Physician’s choice Phase II Status Recruiting Sponsor Sarcoma Alliance for Research through Collaboration (SARC) For further information please also consult https://clinicaltrials.gov/study/NCT06942442 This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell…
Read More